Sivelestat

Sivelestat

SCHEMBL29490347

CC(C)(C)C(=O)Oc1ccc(S(=O)(=O)Nc2ccccc2C(=O)NCC(=O)[O-])cc1.O.O.O.O.[Na+]

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ELANE

The experimentally established mechanism targets of Sivelestat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ELANE known ✓ P08246 16/20 0.68
PRTN3 P24158 12/20 0.68
KDM4E B2RXH2 2/20 0.48
GAA P10253 2/20 0.48
HSD17B10 Q99714 1/20 0.48
LMNA P02545 2/20 0.46
HTT P42858 2/20 0.46
NPC1 O15118 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
ALDH1A1 P00352 1/20 0.46
TP53 P04637 1/20 0.46
HPGD P15428 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
KCNA5 P22460 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sivelestat SCHEMBL7107254 1.00 ELANE (0.68) ELANEPRTN3KDM4EGAAHSD17B10
Sivelestat SCHEMBL29677633 0.99 ELANE (0.69) ELANEPRTN3KDM4EGAAHSD17B10
Sivelestat SCHEMBL4411778 0.99 ELANE (0.69) ELANEPRTN3KDM4EGAAHSD17B10
Sivelestat SCHEMBL6690886 0.91 ELANE (0.69) ELANEPRTN3KDM4EGAAHSD17B10
Sivelestat SCHEMBL30864380 0.91 ELANE (0.69) ELANEPRTN3KDM4EGAAHSD17B10
Sivelestat SCHEMBL597819 0.90 ELANE (0.68) ELANEPRTN3KDM4EGAAHSD17B10
Sivelestat SCHEMBL1499929 0.90 ELANE (0.68) ELANEPRTN3KDM4EGAAHSD17B10
Sivelestat SCHEMBL4411781 0.90 ELANE (0.71) ELANEPRTN3KDM4EGAAHSD17B10
SCHEMBL7267891 0.90 ELANE (0.71) ELANEPRTN3KDM4EGAAHSD17B10
Sivelestat SCHEMBL123221 0.90 ELANE (0.71) ELANEPRTN3KDM4EGAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4744663-A2 SKIN COMPOSITION Eaderm Co., Ltd. (JP) 2026-05-20 EP disclosed
EP-4205750-B1 NADPH OXIDASE INHIBITOR FOR SUPPRESSING OR IMPROVING HAIR LOSS OR TREATING ALOPECIA EADERM CO LTD (JP) 2025-04-09 EP disclosed
WO-2025049724-A1 COMPOSITIONS AND METHODS FOR TREATING PLEURAL SPACE INFECTIONS AND HEMOTHORAX BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 2025-03-06 WO disclosed
WO-2024254398-A2 MODULATION OF NEUTROPHIL ACTIVATION AND NEUTROPHIL EXTRACELLULAR TRAP (NET) FORMATION REDD PHARMACEUTICALS, INC. (US) 2024-12-12 WO disclosed
WO-2024192873-A1 USE OF SMALL MOLECULE COMPOUND HAVING NAPHTHYLAMINE STRUCTURE 杭州天玑济世生物科技有限公司 2024-09-26 WO disclosed
WO-2024193529-A1 USE OF SMALL-MOLECULE COMPOUND HAVING NAPHTHYLAMINE STRUCTURE 杭州天玑济世生物科技有限公司 2024-09-26 WO disclosed
CN-117982414-B Sivelesta sodium nanocrystalline, dry powder and inhalation powder fog agent thereof and preparation method thereof 暨南大学 2024-07-02 CN disclosed
US-20240207484-A1 CARTILAGE TREATMENT FOR USE IN EYELID RECONSTRUCTION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-06-27 US disclosed
CN-118079006-A Skin composition 国立大学法人东京医科齿科大学 2024-05-28 CN disclosed
CN-117982414-A Sivelesta sodium nanocrystalline, dry powder and inhalation powder fog agent thereof and preparation method thereof 暨南大学 2024-05-07 CN disclosed
US-20240099295-A1 CELL TREATMENT AGENT AYA INC. (JP) 2024-03-28 US disclosed
WO-2024008131-A1 NEW USE OF SIVELESTAT 上海汇伦医药股份有限公司 2024-01-11 WO disclosed
EP-3403673-B1 COMPOSITION FOR PREVENTING OR AMELIORATING LOSS OF HAIR AND GRAYING OF HAIR, AND USE THEREOF UNIV NAT CORP TOKYO MEDICAL & DENTAL (JP) 2023-10-11 EP disclosed
US-20230288403-A1 METHOD FOR INDUCING EXTRACELLULAR TRAP (ET) FORMATION Tridek-One Therapeutics (FR) 2023-09-14 US disclosed
EP-4227684-A1 METHOD FOR INDUCING NEUTROPHIL EXTRACELLULAR TRAP (NET) FORMATION Tridek-One Therapeutics (FR) 2023-08-16 EP disclosed
EP-4205750-A1 COMPOSITIONS FOR SUPPRESSING OR IMPROVING HAIR LOSS AND GRAYING, AND USES THEREOF National University Corporation Tokyo Medical and Dental University (JP) 2023-07-05 EP disclosed
WO-2022232516-A1 CARTILAGE TREATMENT FOR USE IN EYELID RECONSTRUCTION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-11-03 WO disclosed
US-20220331389-A1 SKIN COMPOSITION EADERM CO., LTD. (JP) 2022-10-20 US disclosed
US-11298372-B2 Composition for ameliorating loss of hair and graying of hair, and use thereof NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) 2022-04-12 US disclosed
EP-3978020-A1 SKIN COMPOSITION National University Corporation Tokyo Medical and Dental University (JP) 2022-04-06 EP disclosed